Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients

Size: px
Start display at page:

Download "Examples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients"

Transcription

1

2 Examples: Tables Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients

3 Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried Forward Visit Baseline Week 6 Statistics N Mean Median (etc.) N Mean Median (etc.) p value (3) Active (N=xx) xx xx.x xx xx.x Observed Placebo (N=xx) xx xx.x xx xx.x Active (N=xx) xx xx.x x.xxxx Change from Baseline Placebo (N=xx) xx xx.x x.xxxx (1) ANOVA model: response = Treatment Group + Study Center. (2) ANCOVA model: change = Baseline + Treatment Group + Study Center. (3) Paired t test for change from baseline within Treatment Group. Treatment Group Comparison (p value) x.xxxx (1) x.xxxx (2)

4 Incidence Table 2. Incidence of Body Weight Loss, Baseline to Week 12 Visit / Outcome Statistics Active (N=xx) Placebo (N=xx) Week 12 Body Weight Loss No Body Weight Loss N (pct) xx (xxx.x) xx (xxx.x)

5 Correlations Table 3. Correlation Coefficients for Weight/BMI with Dietary Intake Change from Baseline to End of Study Change from Baseline to End of Study Active Correlation N Placebo Correlation N Weight (kg) Total calories (kcal) Carbohydrate (g) (etc.) Body Mass Index Total calories (kcal) Carbohydrate (g) (etc.) Body Mass Index % of Calories from Carbohydrate (etc.)

6 SDTM Files Vital Signs: Height and Weight (VS) Food Frequency Questionnaire: dietary intake and analysis (QS)

7 SDTM Files: VS USUBJID VISIT VSTESTCD VSSTRESN VSSTAT BASELINE HEIGHT xx BASELINE WEIGHT xx WEEK 6 HEIGHT xx WEEK 6 WEIGHT xx WEEK 12 WEIGHT xx WEEK 12 HEIGHT. NOT DONE

8 SDTM Files: QS QSCAT = [name of questionnaire] QSSCAT QSTESTCD QSTEST QSORRES QSSTRESN VISIT Raw Questionnaire Response COLDCFR Cold cereal, Freq last wk 3 4 DAYS LAST WEEK 4 BASELINE Raw Questionnaire Response COLDCQU Cold cereal, Quan each 1 BOWL 2 BASELINE Dietary Analysis Dietary Analysis TOTCAL Total calories BASELINE CARB Carbohydrate BASELINE

9 Plan for ADaM File ADDIET Include nonmissing VSSTRESN, QSSTRESN Calculate BMI = [weight (kg)] / [height (m)] 2 Calculate percent of total calories from carbohydrate, fat, protein

10 Compute BMI AVISIT PARAMCD PARAMTYP SRCDOM SRCVAR SRCSEQ Baseline HEIGHT VS VSSTRESN xx Baseline WEIGHT VS VSSTRESN xx Baseline BMI DERIVED Week 6 HEIGHT VS VSSTRESN xx Week 6 WEIGHT VS VSSTRESN xx Week 6 BMI DERIVED

11 Compute PCTCARB AVISIT PARAMCD PARAMTYP SRCDOM SRCVAR SRCSEQ Baseline CARB QS QSSTRESN xx Baseline TOTCAL QS QSSTRESN xx Baseline PCTCARB DERIVED Week 6 CARB QS QSSTRESN xx Week 6 TOTCAL QS VSSTRESN xx Week 6 PCTCARB DERIVED

12 Parameters PARAM PARAMCD PARAMTYP Body Mass Index BMI DERIVED Carbohydrate (grams) CARB Height (cm) HEIGHT % of Calories from Carbohydrate PCTCARB DERIVED % of Calories from Fat PCTFAT DERIVED % of Calories from Protein PCTPROT DERIVED Total calories (kcal) TOTCAL Weight (kg) WEIGHT

13 Baseline flag AVISIT PARAMCD PARAMTYP ABLFL Baseline BMI DERIVED Y Baseline CARB Y Baseline HEIGHT Y Baseline PCTCARB DERIVED Y Baseline TOTCAL Y Baseline WEIGHT Y

14 Compute LOCF BMI AVISIT VISIT PARAMCD PARAMTYP DTYPE SRCDOM SRCVAR SRCSEQ Baseline BASELINE BMI DERIVED Week 6 WEEK 6 BMI DERIVED Week 12 WEEK 6 BMI DERIVED LOCF

15 Average Over Visits AVISIT PARAMCD PARAMTYP DTYPE SRCDOM SRCVAR SRCSEQ Post Baseline CARB AVERAGE Post Baseline PCTCARB DERIVED AVERAGE Post Baseline TOTCAL AVERAGE

16 Dietary Parameters AVISIT PARAMCD PARAMTYP DTYPE SRCDOM SRCVAR SRCSEQ Baseline CARB QS QSSTRESN xx Baseline TOTCAL QS QSSTRESN xx Baseline PCTCARB DERIVED Week 6 CARB QS QSSTRESN xx Week 6 TOTCAL QS QSSTRESN xx Week 6 PCTCARB DERIVED Week 12 CARB QS QSSTRESN xx Week 12 TOTCAL QS QSSTRESN xx Week 12 PCTCARB DERIVED Post Baseline CARB AVERAGE Post Baseline PCTCARB DERIVED AVERAGE Post Baseline TOTCAL AVERAGE

17 AVAL, BASE, CHG AVISIT PARAMCD AVAL BASE CHG ABLFL Baseline BMI x.x x.x Y Baseline HEIGHT x.x x.x Y Baseline CARB x.x x.x Y Baseline TOTCAL x.x x.x Y Baseline PCTCARB x.x x.x Y Baseline WEIGHT x.x x.x Y Week 6 BMI x.x x.x x.x Week 6 HEIGHT x.x x.x x.x Week 6 CARB x.x x.x x.x Week 6 TOTCAL x.x x.x x.x Week 6 PCTCARB x.x x.x x.x Week 6 WEIGHT x.x x.x x.x

18 Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried Forward Visit Baseline Week 6 Statistics N Mean Median (etc.) N Mean Median (etc.) p value (3) Active (N=xx) xx xx.x xx xx.x Observed Placebo (N=xx) xx xx.x xx xx.x Active (N=xx) xx xx.x x.xxxx Change from Baseline Placebo (N=xx) xx xx.x x.xxxx (1) ANOVA model: response = Treatment Group + Study Center. (2) ANCOVA model: change = Baseline + Treatment Group + Study Center. (3) Paired t test for change from baseline within Treatment Group. Treatment Group Comparison (p value) x.xxxx (1) x.xxxx (2)

19 Results Metadata: Table 1 Display Identifier: Table 1 Display Name: Table 1. Body Mass Index using Last Observation Carried Forward Result Identifier Param Paramcd Analysis Variable Dataset Selection Criteria Documentation Programming Statements (SAS ) Observed baseline Treatment Group Comparison p value Body Mass Index BMI AVAL ADDIET AVISITN = 0 and ITTFL = Y Use Type III sums of squares for all models, and pooled site number proc glm; class trtpn sitegr1n; model aval = trtpn sitegr1n; Observed postbaseline LS means Body Mass Index BMI AVAL ADDIET AVISITN > 0 and ITTFL = Y proc glm; by avisitn; class trtpn sitegr1n; model aval = base trtpn sitegr1n; lsmeans trtpn;

20 Results Metadata: Table 1 Display Identifier: Table 1 Display Name: Table 1. Body Mass Index using Last Observation Carried Forward Result Identifier Param Paramcd Analysis Variable Dataset Selection Criteria Document ation Programming Statements (SAS ) Change LS means and Treatment Group Comparison p value (footnote 2) Body Mass Index BMI CHG ADDIET AVISITN > 0 and ITTFL = Y Model with no interaction terms proc glm; by avisitn; class trtpn sitegr1n; model chg = base trtpn sitegr1n; lsmeans trtpn; p value (footnote 3) Body Mass Index BMI CHG ADDIET AVISITN > 0 and ITTFL = Y Paired t test proc means prt nway; class avisitn trtpn; var chg;

21 Categorize Weight Change AVISIT PARAMCD AVAL BASE CHG CHGCAT1 Baseline WEIGHT x.x x.x Week 6 WEIGHT x.x x.x 1.3 Body Weight Loss Week 12 WEIGHT x.x x.x 0.9 No Body Weight Loss

22 Incidence Table 2. Incidence of Body Weight Loss, Baseline to Week 12 Visit / Outcome Statistics Active (N=xx) Placebo (N=xx) Week 12 Body Weight Loss No Body Weight Loss N (pct) xx (xxx.x) xx (xxx.x)

23 Results Metadata: Table 2 Display Identifier: Table 2 Display Name: Incidence of Body Weight Loss, Baseline to Week 12 Result Identifier Param Paramcd Analysis Variable Weight (kg) Dataset Selection Criteria Documentation Programming Statements (SAS ) WEIGHT CHGCAT1 ADDIET ITTFL = Y and CHGCAT1N in (1,2) and AVISIT = Week 12 CHGCAT1N = 1 means body weight loss, 2 = no body weight loss.

24 Correlations Table 3. Correlation Coefficients for Weight/BMI with Dietary Intake Change from Baseline to End of Study Change from Baseline to End of Study Active Correlation N Placebo Correlation N Weight (kg) Total calories (kcal) Carbohydrate (g) (etc.) Body Mass Index Total calories (kcal) Carbohydrate (g) (etc.) Body Mass Index % of Calories from Carbohydrate (etc.)

25 Correlations: tasks Only visits where all parameters were measured (no LOCF) Change from baseline to last such postbaseline visit

26 All values measured Flag visits where all parameters measured Easy when denormalized: if nmiss(height,weight,carb,totcal) = 0 then ANL01FL = Y ; AVISIT HEIGHT WEIGHT TOTCAL CARB ANL01FL Baseline x.x x.x x.x x.x Y Week 6 x.x x.x x.x x.x Y

27 All values measured Then transpose: AVISIT PARAMCD CHG ABLFL ANL01FL Baseline CARB Y Y Baseline HEIGHT Y Y Baseline TOTCAL Y Y Baseline WEIGHT Y Y Week 6 CARB x.x Y Week 6 HEIGHT x.x Y Week 6 TOTCAL x.x Y Week 6 WEIGHT x.x Y

28 Last visit with all measured AVISIT PARAMCD CHG ABLFL ANL01FL ANL02FL Baseline CARB Y Y Baseline HEIGHT Y Y Baseline TOTCAL Y Y Baseline WEIGHT Y Y Week 6 CARB x.x Y Week 6 HEIGHT x.x Y Week 6 TOTCAL x.x Y Week 6 WEIGHT x.x Y Week 12 CARB x.x Y Y Week 12 HEIGHT x.x Y Y Week 12 TOTCAL x.x Y Y Week 12 WEIGHT x.x Y Y

29 All measured at baseline AVISIT PARAMCD CHG ABLFL ANL01FL ANL02FL ANL03FL Baseline CARB Y Y Y Baseline HEIGHT Y Y Y Baseline TOTCAL Y Y Y Baseline WEIGHT Y Y Y Week 6 CARB x.x Y Y Week 6 HEIGHT x.x Y Y Week 6 TOTCAL x.x Y Y Week 6 WEIGHT x.x Y Y Week 12 CARB x.x Y Y Y Week 12 HEIGHT x.x Y Y Y Week 12 TOTCAL x.x Y Y Y Week 12 WEIGHT x.x Y Y Y

30 All not measured at baseline AVISIT PARAMCD CHG ABLFL ANL01FL ANL02FL ANL03FL Baseline CARB Y Baseline TOTCAL Y Baseline WEIGHT Y Week 6 CARB x.x Y Week 6 HEIGHT x.x Y Week 6 TOTCAL x.x Y Week 6 WEIGHT x.x Y Week 12 CARB x.x Y Y Week 12 HEIGHT x.x Y Y Week 12 TOTCAL x.x Y Y Week 12 WEIGHT x.x Y Y

31 Record Selection ANL02FL = Y AND ANL03FL = Y AVISIT PARAMCD CHG ABLFL ANL01FL ANL02FL ANL03FL Week 12 CARB x.x Y Y Y Week 12 HEIGHT x.x Y Y Y Week 12 TOTCAL x.x Y Y Y Week 12 WEIGHT x.x Y Y Y

32 In SAS proc sort data=addiet out=tabledata; by trtp usubjid paramcd; where anl02fl = Y and anl03fl = Y ; run; proc transpose data=tabledata out=trandata; by trtp usubjid; id paramcd; var chg; run; proc corr data=trandata pearson; by trtp; var weight bmi; with totcal carb (other parameters); run;

33 Record Selection (actual) proc sql; create table main as select usubjid, trtpn, paramcd, chg from adam.addiet where ittfl = Y and anl03fl = Y and ( (avisit = Post Baseline and paramcd in ( TOTCAL, CARB, )) or (paramcd in ( BMI, WEIGHT ) and anl02fl = Y ) ) order by trtpn, usubjid, paramcd; quit;

34 Analysis File Metadata Dataset Description Structure Purpose Keys Class of Dataset ADDIET Diet and weight analysis file One record per subject per parameter per analysis visit Analysis STUDYID, USUBJID, PARAMCD, AVISIT BDS Location addiet.xpt

35 Bonus Example! VS Toxicity Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials Fever Vital Signs Tachycardia beats per minute Bradycardia beats per minute Hypertension (systolic) mm Hg Hypertension (diastolic) mm Hg Hypotension (systolic) mm Hg Respiratory rate breaths per minute Mild (Grade 1) C F Moderate (Grade 2) C F > < > > <80 Severe (Grade 3) C F >40 C >104 F >25 Intubation Potentially Life Threatening (Grade 4) ER visit or hospitalization for arrhythmia ER visit or hospitalization for arrhythmia ER visit or hospitalization for malignant hypertension ER visit or hospitalization for malignant hypertension ER visit or hospitalization for hypotensive shock

36 VS Toxicity Shift Table N (%) with No increase Increase by 1 grade Increase by 2 grades Increase by 3 grades Increase by 4 grades (only possible with Fever based on vital signs alone)

37 ADVS Design Approach: ATOXGR, BTOXGR: Assign toxicity grade AVALCAT1, BASECAT1: Categorize results into Normal, Fever, Tachycardia, Bradycardia, Hypertension (systolic), etc. Ranges for both dependent on PARAMCD SHIFT1: Assign shift as No increase, Increase by 1 grade, Increase by 2 grades, etc.

38 ADVS Design For systolic blood pressure: (row) USUBJID PARAMCD AVISIT AVAL ATOXGR AVALCAT SYSBP Baseline Normal SYSBP Week Hypertension (systolic) SYSBP Baseline Normal SYSBP Week Hypotension (systolic) (row) BASE BTOXGR BASECAT1 SHIFT1 SHIFT1N ABLFL Normal Y Normal Increase by 1 grade Normal Y Normal Increase by 3 grades 3

39 ADVS Design The shift is based on ATOXGR, BTOXGR without reference to type of toxicity Use AVALCAT1 to select type of toxicity where PARAMCD = SYSBP and SHIFT1 ne and AVALCAT1 in ( Normal, Hypertension (systolic) ); where PARAMCD = TEMP and SHIFT1 ne and AVALCAT1 in ( Normal, Fever );

40 Karen G. Malley Malley Research Programming, Inc. Tel:

Frequency Tables Aspects to Consider / PhUSE - Industry Starters / Katja Glaß

Frequency Tables Aspects to Consider / PhUSE - Industry Starters / Katja Glaß Frequency Tables Aspects to Consider 15.10.2014 / PhUSE - Industry Starters / Katja Glaß Agenda Introduction Do the double programming Demography Adverse Events Laboratory Summary and further aspects Page

More information

CDISC Journey in Solid Tumor using RECIST 1.1. Kevin Lee Statistician/CDISC Consultant/Programmer

CDISC Journey in Solid Tumor using RECIST 1.1. Kevin Lee Statistician/CDISC Consultant/Programmer CDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee Statistician/CDISC Consultant/Programmer Disclaimer Any views or opinions presented in this presenta1on are solely those of the author and do not

More information

Standard Methods for Analysis and Reporting of VAS or NRS Derived Pain Relief Response Scores

Standard Methods for Analysis and Reporting of VAS or NRS Derived Pain Relief Response Scores Standard Methods for Analysis and Reporting of VAS or NRS Derived Pain Relief Response Scores James R. Johnson, PhD Sr. Director Biostatistics and Data Sciences Flexion Therapeutics, Inc. Presentation

More information

ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go?

ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? ABSTRACT PharmaSUG 2017 - Paper DS17 ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? Jack Shostak, Duke Clinical Research Institute ADaM has variables that allow you to cluster,

More information

Michigan Neuropathy Screening Instrument (MNSI)

Michigan Neuropathy Screening Instrument (MNSI) Michigan Neuropathy Screening Instrument () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Hospital Anxiety and Depression Scale (HADS)

Hospital Anxiety and Depression Scale (HADS) Hospital Anxiety and Depression Scale (HADS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and

More information

Clinical Global Impression (CGI)

Clinical Global Impression (CGI) Clinical Global Impression (CGI) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Epworth Sleepiness Scale (ESS)

Epworth Sleepiness Scale (ESS) Epworth Sleepiness Scale (ESS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaires Sub-team Notes to Readers This

More information

Neuropathic Pain Scale (NPS)

Neuropathic Pain Scale (NPS) Neuropathic Pain Scale (NPS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and the CDISC Questionnaire

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Let s Create Standard Value Level Metadata

Let s Create Standard Value Level Metadata PRA Health Sciences PhUSE US Connect 2019 Paper DS12 February 27, 2019 David Fielding Value Level Metadata Value Level Metadata is an important part of the Define-XML that allows us to explain our study

More information

Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0

Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0 Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0 Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v2.0 Team

More information

Graph Display of Patient Profile Using SAS

Graph Display of Patient Profile Using SAS PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile

More information

Barnes Akathisia Rating Scale (BARS)

Barnes Akathisia Rating Scale (BARS) Barnes Akathisia Rating Scale () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes to Readers This

More information

Brief Psychiatric Rating Scale-Anchored (BPRS-A)

Brief Psychiatric Rating Scale-Anchored (BPRS-A) Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Disability Assessment for Dementia (DAD)

Disability Assessment for Dementia (DAD) Disability Assessment for Dementia (DAD) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v1.1 Team and the CDISC Questionnaire

More information

Short-Form McGill Pain Questionniare-2 (SHORT-FORM MPQ-2)

Short-Form McGill Pain Questionniare-2 (SHORT-FORM MPQ-2) Short-Form McGill Pain Questionniare-2 ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)

Columbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE) Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial

More information

Brief Psychiatric Rating Scale-Anchored (BPRS-A)

Brief Psychiatric Rating Scale-Anchored (BPRS-A) Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes

More information

Pain Relief (PR) Notes to Readers

Pain Relief (PR) Notes to Readers Pain (PR) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations, Innovations, Opportunities,

More information

ADaM Tips for Exposure Summary

ADaM Tips for Exposure Summary ABSTRACT PharmaSUG China 2016 Paper 84 ADaM Tips for Exposure Summary Kriss Harris, SAS Specialists Limited, Hertfordshire, United Kingdom Have you ever created the Analysis Dataset for the Exposure Summary

More information

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep

More information

CDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee PhUSE conference Oct 14th, 2013

CDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee PhUSE conference Oct 14th, 2013 CDISC Journey in Solid Tumor using RECIST 1.1 Kevin Lee PhUSE conference Oct 14th, 2013 Disclaimer Any views or opinions presented in this presentation are solely those of the author and do not necessarily

More information

Hamilton Depression Rating Scale 17-Item (HAMD 17)

Hamilton Depression Rating Scale 17-Item (HAMD 17) Hamilton Depression Rating Scale -Item ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,

More information

Analysis Datasets for Baseline Characteristics and Exposure Time for Multi-stage Clinical Trials

Analysis Datasets for Baseline Characteristics and Exposure Time for Multi-stage Clinical Trials Analysis Datasets for Baseline Characteristics and Exposure Time for Multi-stage Clinical Trials Kim Umans, Katherine Riester, Manjit McNeill, Wei Liu, and Lukasz Kniola PhUSE 2016, CD06, Barcelona Introduction

More information

Integrated ADSL. PhUSE Nate Freimark/Thomas Clinch Theorem Clinical Research

Integrated ADSL. PhUSE Nate Freimark/Thomas Clinch Theorem Clinical Research Integrated ADSL PhUSE 2012-10-17 Nate Freimark/Thomas Clinch Theorem Clinical Research ADSL - Not Without Challenges Where to Begin Source Data One ADSL or Two Number of Records per Subject Update or Create

More information

AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd.

AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd. PharmaSUG 2016 - Paper IB11 AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd., Pune, India ABSTRACT Adverse event (AE) summary tables

More information

A SAS sy Study of ediary Data

A SAS sy Study of ediary Data A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)

More information

Statistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue

Statistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS

More information

Immediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020

Immediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of

More information

Clinical Trial Synopsis TL-OPI-518, NCT#

Clinical Trial Synopsis TL-OPI-518, NCT# Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride

More information

Imputing Dose Levels for Adverse Events

Imputing Dose Levels for Adverse Events Paper HO03 Imputing Dose Levels for Adverse Events John R Gerlach & Igor Kolodezh CSG Inc., Raleigh, NC USA ABSTRACT Besides the standard reporting of adverse events in clinical trials, there is a growing

More information

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301 SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYCL

Summary ID# Clinical Study Summary: Study B4Z-MC-LYCL CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine

More information

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies

Design and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies PharmaSUG China Design and Construct Efficacy Analysis s in Late Phase Oncology Studies Huadan Li, MSD R&D (China) Co., Ltd., Beijing, China Changhong Shi, MSD R&D (China) Co., Ltd., Beijing, China ABSTRACT

More information

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve

More information

Summary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ

Summary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ CT Registry ID#4668 Page 1 Summary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ Date summary approved by Lilly: 09 August 2005 Title of Study: Safety and Efficacy of Atomoxetine or Atomoxetine Plus

More information

Pharmaceutical Applications

Pharmaceutical Applications Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients

More information

OCCDS Creating flags or records. Rob Wartenhorst PhUSE Barcelona 2016

OCCDS Creating flags or records. Rob Wartenhorst PhUSE Barcelona 2016 OCCDS Creating flags or records Rob Wartenhorst PhUSE Barcelona 2016 Introduction ADAE, ADCM and ADMH originally set up using ADAE structure. After release of OCCDS guide attempted to implement the occurrence

More information

Stat Wk 9: Hypothesis Tests and Analysis

Stat Wk 9: Hypothesis Tests and Analysis Stat 342 - Wk 9: Hypothesis Tests and Analysis Crash course on ANOVA, proc glm Stat 342 Notes. Week 9 Page 1 / 57 Crash Course: ANOVA AnOVa stands for Analysis Of Variance. Sometimes it s called ANOVA,

More information

EVERY DAY A GUIDE TO KNOW YOUR NUMBERS

EVERY DAY A GUIDE TO KNOW YOUR NUMBERS EVERY DAY A GUIDE TO KNOW YOUR NUMBERS WHAT IS BMI? Measuring your Body Mass Index (BMI) is a useful way to determine if you are at a healthy weight. Excess weight can increase your risk of heart disease,

More information

ADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc.

ADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc. ADaM Considerations and Content in the TA User Guides Susan J Kenny, PhD Maximum Likelihood, Inc. Topics to Discuss Focus of ADaM content Overview of TAUGs with ADaM content Specific ADaM content in selected

More information

Linear Regression in SAS

Linear Regression in SAS 1 Suppose we wish to examine factors that predict patient s hemoglobin levels. Simulated data for six patients is used throughout this tutorial. data hgb_data; input id age race $ bmi hgb; cards; 21 25

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYAX

Summary ID# Clinical Study Summary: Study B4Z-MC-LYAX CT Registry ID#5004 Page 1 Summary ID# 5004 Clinical Study Summary: Study B4Z-MC-LYAX A Randomized, Double-Blind, Placebo-Controlled Study of Hydrochloride in Adolescents with Attention-Deficit/Hyperactivity

More information

Support for Acetaminophen 1000 mg Over-the-Counter Dose:

Support for Acetaminophen 1000 mg Over-the-Counter Dose: Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,

More information

Information Sheet. Weight. Accessible information about weight for adults with an eating disorder

Information Sheet. Weight. Accessible information about weight for adults with an eating disorder Information Sheet Weight Accessible information about weight for adults with an eating disorder ? Why do I need to restore my body weight? Weight restoration in eating disorders is integral to recovery

More information

Individual Study Table Referring to Item of the Submission: Volume: Page:

Individual Study Table Referring to Item of the Submission: Volume: Page: 2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:

More information

Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies

Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies T07-2008 Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies Daojun Mo 1, Xia Li 2 and Alan Zimmermann 1 1 Eli Lilly and Company, Indianapolis, IN 2 inventiv Clinical

More information

A study of academic stress and its effect on vital parameters in final year medical students at SAIMS Medical College, Indore, Madhya Pradesh

A study of academic stress and its effect on vital parameters in final year medical students at SAIMS Medical College, Indore, Madhya Pradesh Biomedical Research 2011; 22 (3): 361-365 A study of academic stress and its effect on vital parameters in final year medical students at SAIMS Medical College, Indore, Madhya Pradesh Balkishan Sharma,

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

SYNOPSIS. Publications No publications at the time of writing this report.

SYNOPSIS. Publications No publications at the time of writing this report. Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release

More information

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances

More information

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY MATERIAL SUPPLEMENTARY MATERIAL The effect of current dietary provided by frequent advice versus food delivery on weight loss and cardiovascular risk factors. A Randomized Clinical Trial. David JA Jenkins, Beatrice

More information

Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC

Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBR

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBR CT Registry ID#6934 Page 1 Summary ID# 6934 Clinical Study Summary: Study B4Z-MC-LYBR Title of Study: A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate

More information

PATIENT INFORMATION. Medicine To Treat: H ypertension. Patient Awareness and Self-Care

PATIENT INFORMATION. Medicine To Treat: H ypertension. Patient Awareness and Self-Care PATIENT INFORMATION Medicine To Treat: H ypertension Patient Awareness and Self-Care WHAT IS BLOOD PRESSURE AND HIGH BLOOD PRESSURE? Blood pressure is the force generated as your heart pumps blood and

More information

NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet

NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet FASTING 16 hours a day EXCERCISE 150 min a week DIET Low carb NOSM Northern Research Conference, Kenora, 2018 R Minty, T O Driscoll, L Kelly,

More information

Sample Resting Metabolic Rate Test Results

Sample Resting Metabolic Rate Test Results Sample Resting Metabolic Rate Test Results Innerscan Results Date: Sample Height (CM) 183 Weight (Kg) 89.3 Body Fat (%) 24.3 Body Water (%) 51.4 Muscle Mass (Kg) 64.3 Bone Mass (Kg) 3.3 Physique Rating

More information

2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National

More information

Hungry Mice. NP: Mice in this group ate as much as they pleased of a non-purified, standard diet for laboratory mice.

Hungry Mice. NP: Mice in this group ate as much as they pleased of a non-purified, standard diet for laboratory mice. Hungry Mice When laboratory mice (and maybe other animals) are fed a nutritionally adequate but near-starvation diet, they may live longer on average than mice that eat a normal amount of food. In this

More information

Digestive Project Part 1

Digestive Project Part 1 Digestive Project Part 1 Purpose: For Part 1 of the Digestive System project you will be researching various minerals and vitamins that are essential for the body. Background Info. 1. What is the difference

More information

SUPPLEMENTARY DATA. Supplementary Methods

SUPPLEMENTARY DATA. Supplementary Methods Supplementary Methods Chronic kidney disease stage 4 or 5 Current diabetic foot with ulcer, soft tissue infection or necrosis Unstable angina, myocardial infarction, or cerebrovascular accident over the

More information

Adalimumab M Clinical Study Report Final R&D/16/0603

Adalimumab M Clinical Study Report Final R&D/16/0603 Methodology (Continued): The 70-day safety follow-up period started from the last dose of study drug, but was not required for any subject who initiated commercial Humira after study completion. Additional

More information

Implementing Patient Report Outcome Data in Clinical Trials Analysis

Implementing Patient Report Outcome Data in Clinical Trials Analysis PharmaSUG 2017 - Paper PO04 Implementing Patient Report Outcome Data in Clinical Trials Analysis ABSTRACT Qi Wang, Amgen, Thousand Oaks, CA Over the recent decades, Health-Related Quality of Life (HRQoL)

More information

Paliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1

Paliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1 Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed

More information

Intro to SPSS. Using SPSS through WebFAS

Intro to SPSS. Using SPSS through WebFAS Intro to SPSS Using SPSS through WebFAS http://www.yorku.ca/computing/students/labs/webfas/ Try it early (make sure it works from your computer) If you need help contact UIT Client Services Voice: 416-736-5800

More information

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers). Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBU

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBU CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate

More information

RICHMOND PARK SCHOOL LIFESTYLE SCREENING REPORT Carmarthenshire County Council

RICHMOND PARK SCHOOL LIFESTYLE SCREENING REPORT Carmarthenshire County Council RICHMOND PARK SCHOOL LIFESTYLE SCREENING REPORT 2016 Carmarthenshire County Council WHY LEAD A HEALTHY LIFESTYLE? A nutritious, well-balanced diet along with physical activity and refraining from smoking

More information

Allergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel

Allergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple

More information

a) Vitality Compass Life Expectancy

a) Vitality Compass Life Expectancy PGCE: LIFE ORIENTATION LEARNING AREA STUDIES COURSE OUTLINE 2017 GET Health & Wellness Workbook Created by Desiree Lee http://loilifeo.weebly.com/ All lectures and links and notes are available on this

More information

Chapter 6 Measures of Bivariate Association 1

Chapter 6 Measures of Bivariate Association 1 Chapter 6 Measures of Bivariate Association 1 A bivariate relationship involves relationship between two variables. Examples: Relationship between GPA and SAT score Relationship between height and weight

More information

Chapter 9 Vital Signs and SAMPLE History DOT Directory

Chapter 9 Vital Signs and SAMPLE History DOT Directory Chapter 9 Vital Signs and SAMPLE History U.S. Objectives U.S. Objectives are covered and/or supported by the PowerPoint Slide Program and Notes for Emergency Care, 11th Ed. Please see the Chapter 9 correlation

More information

HIGH ENERGY AND FAT INTAKE BETWEEN DORMITORY AND NON-DORMITORY STUDENTS IN CHULALONGKORN UNIVERSITY, THAILAND

HIGH ENERGY AND FAT INTAKE BETWEEN DORMITORY AND NON-DORMITORY STUDENTS IN CHULALONGKORN UNIVERSITY, THAILAND HIGH ENERGY AND FAT INTAKE BETWEEN DORMITORY AND NON-DORMITORY STUDENTS IN CHULALONGKORN UNIVERSITY, THAILAND Patimanukaseam P, Punya-ngarm Y. Department of Biochemistry, Faculty of Dentistry, Chulalongkorn

More information

Clinical Trial Study Synopsis

Clinical Trial Study Synopsis Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency

More information

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized

More information

PharmaSUG 2018 Paper AD-02

PharmaSUG 2018 Paper AD-02 PharmaSUG 2018 Paper AD-02 Derivations of Response Status from SDTM Domains using RECIST 1.1 Christine Teng, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ USA Pang Lei, Merck Research Laboratories,

More information

Study Center(s): The study was conducted at 39 study sites in Japan.

Study Center(s): The study was conducted at 39 study sites in Japan. SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01

More information

2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:

2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority

More information

Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ

Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients

More information

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-

More information

Lindsey Dorflinger, Ph.D. VA Connecticut Healthcare System Yale School of Medicine

Lindsey Dorflinger, Ph.D. VA Connecticut Healthcare System Yale School of Medicine Lindsey Dorflinger, Ph.D. VA Connecticut Healthcare System Yale School of Medicine Acknowledgments Robin Masheb, PhD Carlos Grilo, PhD Barbara Rolls, PhD Diane Mitchell, MS, RD No conflicts of interest

More information

Unified Parkinson's Disease Rating Scale UPDRS

Unified Parkinson's Disease Rating Scale UPDRS Unified Parkinson's Disease Rating Scale Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and National Institute of Neurological

More information

Standards for Analyzable Submission Datasets for Directed Safety Analyses

Standards for Analyzable Submission Datasets for Directed Safety Analyses Standards for Analyzable Submission Datasets for Directed Safety Analyses Michael Nessly Director, Clinical Biostatistics Merck Research Labs CDISC Analysis Dataset Models Team (ADaM) nesslym@merck.com

More information

Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ

Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ ABSTRACT: If you use SAS Proc Report frequently, you will be familiar with the flow option. The flow option wraps

More information

Who is Exante Diet suitable for?

Who is Exante Diet suitable for? Who is Exante Diet suitable for? www.exantediet.com Who is Exante Diet Suitable For? Exante Diet has a programme for almost everyone. Whether you re looking to lose 2lbs or 10 stone, you can do it with

More information

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page: SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With

More information

Home Food Resources for You Consumers. Food

Home Food Resources for You Consumers. Food Home Food Resources for You Consumers Food How to Understand and Use the Nutrition Facts Label On this page: The Nutrition Facts Panel - An Overview The Serving Size Calories (and Calories from Fat) The

More information

UNIVERSIDAD*DE*COSTA*RICA*

UNIVERSIDAD*DE*COSTA*RICA* * * * UNIVERSIDAD*DE*COSTA*RICA* CRELES*Pre21945* Costa*Rican*Longevity*and*Healthy*Aging*Study* Recoded*Variables,*Wave*1* Luis*Rosero2Bixby* William*H.*Dow* Xinia*Fernández* Coverage:Costa*Rica,*population*aged*60+*in*2005*

More information

BCH 445 Biochemistry of nutrition Dr. Mohamed Saad Daoud

BCH 445 Biochemistry of nutrition Dr. Mohamed Saad Daoud BCH 445 Biochemistry of nutrition Dr. Mohamed Saad Daoud 1 Energy Needs & Requirements Food is the only source of body which undergoes Metabolism and liberate / Generates Energy required for vital activities

More information

Clinical Study Report. Arbonne Essentials Products Arbonne Evolution Products

Clinical Study Report. Arbonne Essentials Products Arbonne Evolution Products Clinical Study Report Arbonne Essentials Products Arbonne Evolution Products CLINICAL STUDY A 16 week study assessing the effect of dietary supplements and recommended calorie restrictions and regular,

More information

Things you need to know about the Normal Distribution. How to use your statistical calculator to calculate The mean The SD of a set of data points.

Things you need to know about the Normal Distribution. How to use your statistical calculator to calculate The mean The SD of a set of data points. Things you need to know about the Normal Distribution How to use your statistical calculator to calculate The mean The SD of a set of data points. The formula for the Variance (SD 2 ) The formula for the

More information

Table S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group

Table S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group Table S1: Nutrient composition of cracker and almond snacks Cracker* Almond** Weight, g 77.5 g (5 sheets) 56.7 g (2 oz.) Energy, kcal 338 364 Carbohydrate, g (kcal) 62.5 12.6 Dietary fiber, g 2.5 8.1 Protein,

More information

Analysis of Oncology Studies for Programmers and Statisticians

Analysis of Oncology Studies for Programmers and Statisticians PharmaSUG 2018 DS06 Analysis of Oncology Studies for Programmers and Statisticians Kevin Lee, Clindata Insight, Moraga, CA ABSTRACT Compared to other therapeutic studies, oncology studies are generally

More information

P105 STUDY REPORT A Double Blind Placebo Controlled Trial of the Effect of AppTrim

P105 STUDY REPORT A Double Blind Placebo Controlled Trial of the Effect of AppTrim P105 STUDY REPORT A Double Blind Placebo Controlled Trial of the Effect of AppTrim on Appetite Suppression and Obesity Management Targeted Medical Pharma Inc. 1 6/9/2011 12:41 PM Executive Summary Study

More information

PharmaSUG Paper SP01

PharmaSUG Paper SP01 PharmaSUG 2014 - Paper SP01 Factor Analysis of Scale for Assessment of Negative Symptoms using SAS Software Ben Adeyi, Shire Pharmaceuticals, Chesterbrook, PA David Shen, Independent Consultant, Chesterbrook,

More information